Olema Oncology
CA - San FranciscoBiotechnology
Focus: Olema Oncology is a public biotech company focused on CAR T brake technology and oncology/cell therapy development, operating from San Francisco since 2006. The company is advancing precision oncology approaches to enhance CAR T cell therapies and other cancer treatments.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
15-7 this month
Cooling — net -7 jobs in 30d
3 added, 10 removed. Slower than typical.
Should You Work at Olema Oncology?
AI assessmentBest suited for early-stage oncology researchers and manufacturing specialists willing to build platforms in a pre-revenue biotech with a differentiated technology angle.
Why Work Here
- Active hiring across clinical (7 roles), manufacturing (3), and supply chain (3) suggests expansion in development and GMP execution capabilities
- Publicly traded status provides stability and access to capital markets for R&D funding without immediate revenue pressure
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Slowing
Jobs decreasing
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Olema Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.